Cargando…

P855: SYNERGISTIC EFFICACY OF COMBINED SUMOYLATION AND PROTEASOME INHIBITION IN MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Keller, U., Heynen, G., Baumgartner, F., Heider, M., Patra, U., Braune, J., Mertins, P., Müller, S., Bassermann, F., Krönke, J., Wirth, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429163/ http://dx.doi.org/10.1097/01.HS9.0000846300.50278.85

Ejemplares similares

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

EXM 85.5
Publicado: (1985)

The OTUD6B‐LIN28B‐MYC axis determines the proliferative state in multiple myeloma
por: Paulmann, Carmen, et al.
Publicado: (2022)

P855: FERROPTOSIS AS A NEW BCMA-TARGETED IMMUNOTHERAPY OFF-TARGET EFFECT IN MULTIPLE MYELOMA
por: La Spina, Enrico, et al.
Publicado: (2023)

Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy
por: Wirth, Matthias, et al.
Publicado: (2020)

S189: PROTEOGENOMIC LANDSCAPE OF MULTIPLE MYELOMA
por: Ramberger, Evelyn, et al.
Publicado: (2023)

Ocular and periocular tumors in 855 Asian Indian geriatric patients
por: Kaliki, Swathi, et al.
Publicado: (2021)

Correction to Lancet Child Adolesc Health 2019; 3: 855–70
Publicado: (2019)

A Review of The Synergistic Effects of Curcumin with Proteasome Inhibitors in Multiple Myeloma Preclinical Models
por: Pandya, Shaunak K., et al.
Publicado: (2023)

855 Risk Factors for Peripherally Inserted Central Catheter (PICC) Bloodstream Infection (BSI)
por: Kagan, Evgenia, et al.
Publicado: (2014)

Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation
por: Bukkems, Laura H., et al.
Publicado: (2023)

SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma
por: Du, Li, et al.
Publicado: (2022)

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide
por: Du, Li, et al.
Publicado: (2022)

Comparative study of proteasome inhibitory, synergistic antibacterial, synergistic anticandidal, and antioxidant activities of gold nanoparticles biosynthesized using fruit waste materials
por: Patra, Jayanta Kumar, et al.
Publicado: (2016)

855 Double Blind Placebo Controlled Food Challenge Useful to Disconfirm Over Estimated Diagnosis of Cmpa in Children
por: Accomando, S, et al.
Publicado: (2010)

Initial evaluation of [(18)F]-FACBC for PET imaging of multiple myeloma
por: Morath, Volker, et al.
Publicado: (2022)

855. Significance of Invasive Infections due to Methicillin Sensitive Staphylococcus aureus in the neonatal population
por: Riollano, Mariawy, et al.
Publicado: (2020)

855. Impact of FDA Black Box Warning on Fluoroquinolone and Alternative Antibiotic Use in Southeastern US Hospitals
por: Yarrington, Michael, et al.
Publicado: (2018)

Enlace de red Novell y equipos Hp 855, 840 y equipo Sun /
por: Hernández Barrera, Nora Estela
Publicado: (1995)

Path Analysis on Medical Expenditures of 855 Patients with Chronic Kidney Disease in a Hospital in Beijing
por: Liu, Xin, et al.
Publicado: (2018)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples
por: Walsh, Roddy, et al.
Publicado: (2017)

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
por: Mitra, A K, et al.
Publicado: (2017)

Safety of PEGylated recombinant human full‐length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates
por: Stidl, R., et al.
Publicado: (2015)

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
por: Besse, L, et al.
Publicado: (2017)

Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors
por: Bat-Erdene, Ariunzaya, et al.
Publicado: (2016)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)

POS-855 MORTALITY RATE AND ACUTE KIDNEY INJURY PREVALENCE REDUCTION IN COVID-19 CRITICAL PATIENTS TREATED WITH HEMOPERFUSION
por: Barriga-Moreno P, A., et al.
Publicado: (2022)

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
por: Ng, Yuen Lam Dora, et al.
Publicado: (2022)

How Ultrasound Can Be Useful for Staging Chronic Kidney Disease in Dogs: Ultrasound Findings in 855 Cases
por: Perondi, Francesca, et al.
Publicado: (2020)

Comparison of dislocation rates of Teflon and Titanium stapes prostheses: a retrospective survival analysis on 855 patients
por: Gargula, Stéphane, et al.
Publicado: (2023)

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
por: Stroh, Jacob, et al.
Publicado: (2022)

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
por: Chen, John H., et al.
Publicado: (2017)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
por: Merin, Noah M., et al.
Publicado: (2014)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

E2-25K SUMOylation inhibits proteasome for cell death during cerebral ischemia/reperfusion
por: Jeong, Eun Il, et al.
Publicado: (2016)

SUMOylation Protects FASN Against Proteasomal Degradation in Breast Cancer Cells Treated with Grape Leaf Extract
por: Floris, Andrea, et al.
Publicado: (2020)

SUMOylation in Human Pathogenic Fungi: Role in Physiology and Virulence
por: Sahu, Mahima Sagar, et al.
Publicado: (2020)

The Bacterial Proteasome at the Core of Diverse Degradation Pathways
por: Müller, Andreas U., et al.
Publicado: (2019)

Response function of $PbWO_{4}$-detectors to electrons and photons between 50 and 855 MeV energy
por: Novotny, R, et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_q1129nrv4suliu5a265lqclajn